Aucentra discovers and develops oral small molecules for a range of cancers. Our pipeline of candidates includes highly potent and selective, first-in-class CDK inhibitors. Established in 2017, we develop breakthrough classes of drugs to address unmet medical need for some of the most severe cancers. Our novel compounds are more targeted and efficacious than current therapeutics, with less side effects. Aucentra’s deep pipeline of proprietary anti-cancer drugs, developed in partnership with the University of South Australia, includes candidates for the treatment of leukemia, ovarian cancer, glioblastoma, colorectal cancer, breast cancer, prostate cancer, liver cancer and lung cancer.